Canada Markets closed

Inovio Pharmaceuticals, Inc. (INO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.79-0.07 (-0.89%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close7.86
Open7.88
Bid7.79 x 1000
Ask7.82 x 4000
Day's Range7.67 - 7.94
52 Week Range5.81 - 19.00
Volume4,278,833
Avg. Volume4,438,687
Market Cap1.633B
Beta (5Y Monthly)0.65
PE Ratio (TTM)N/A
EPS (TTM)-1.08
Earnings DateMay 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.33
  • Motley Fool

    5 Stocks With 195% to 467% Upside, According to Wall Street

    If the high-water price target for each of the following five stocks were to come to fruition, shareholders would be looking at gains ranging from a low of 195% to as much as 467%. If you're "only" looking to triple your money, analyst Amit Dayal of H.C. Wainwright would suggest putting it to work in hydrogen fuel-cell solutions company Plug Power (NASDAQ: PLUG). Dayal's price target of $78 implies a cool 195% upside from where its shares closed this past weekend.

  • Motley Fool

    Why Inovio Stock Is Jumping Today

    What happened Shares of Inovio Pharmaceuticals (NASDAQ: INO) were jumping 5.9% higher as of 11:07 a.m. EDT on Thursday after rising as much as 13.6% earlier in the session. The big gain came following Inovio's announcement that Brazilian regulators authorized the initiation of a phase 3 clinical study of COVID-19 vaccine candidate INO-4800.

  • Reuters

    UPDATE 2-Inovio to start COVID-19 vaccine trial after Brazil regulator's nod

    Inovio Pharmaceuticals Inc said on Thursday it would start a large study for its experimental COVID-19 vaccine in the next few weeks, after the drugmaker received authorization from Brazil's regulatory agency. The company is currently working on importing the vaccine to Brazil and expects dosing of trial participants to begin in September, Chief Executive Officer Joseph Kim told Reuters. Inovio started developing its COVID-19 DNA vaccine, INO-4800, last year but fell behind rivals after the U.S. Food and Drug Administration (FDA) put the Phase 3 portion of its mid-to-late stage trial on hold for more information on the vaccine delivery device.